{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:29:27Z","timestamp":1791959367005,"version":"4.3.4"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immunogenicity and safety of varicella vaccine (<jats:italic>Varilrix<\/jats:italic><jats:sup>\u2122<\/jats:sup> [Oka\u2010<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content>]; GlaxoSmithKline Vaccines) in adults who had undergone autologous hematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) were assessed (September 2003 to September 2007; <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00792623).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two Oka\u2010<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> doses were given at 4.5 and 6.5\u00a0months post transplantation. Humoral immune responses were assessed using an immunofluorescence assay (anti\u2010varicella zoster virus [<jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content>] antibody; cutoff 1:4) after each vaccine dose. Solicited local (8\u00a0day) and general (43\u00a0day), unsolicited (until day 43) adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) after each vaccine dose and serious adverse events (<jats:styled-content style=\"fixed-case\">SAE<\/jats:styled-content>s) (until 17.5\u00a0months post dose 2) were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 45 patients, 19 were included in the according to protocol cohort for immunogenicity; 15 patients had pre\u2010 and post\u2010vaccination serum samples positive for anti\u2010<jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content> antibodies. Vaccine responses (anti\u2010<jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content> antibody titer \u22651:4 in seronegative patients, and \u22654\u2010fold increase in anti\u2010<jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content> antibody titer in seropositive patients) were elicited by only 2 patients 2\u00a0months post dose 1, and by a single patient 1.5\u00a0months post dose 2. Although no major safety signals were detected, any and Grade 3 solicited <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s that were causally related to vaccination were reported by 44.8% and 10.3% patients, respectively. During the 43\u2010day follow\u2010up period, 3 patients developed varicella\u2010like rash (1 vaccine\u2010type <jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content>). Beyond 43\u00a0days, herpes zoster was reported in 2 patients and wild\u2010type varicella infection in 2 patients (1 was breakthrough infection). Four non\u2010fatal <jats:styled-content style=\"fixed-case\">SAE<\/jats:styled-content>s were reported by patients and considered causally unrelated to vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oka\u2010<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> was poorly immunogenic but safe when given to adults up to 6\u00a0months post autologous <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>, and alternative strategies are required to prevent <jats:styled-content style=\"fixed-case\">VZV<\/jats:styled-content>\u2010associated complications in these populations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12295","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T12:12:05Z","timestamp":1412165525000},"page":"1024-1031","source":"Crossref","is-referenced-by-count":21,"title":["Immunogenicity and safety of a two\u2010dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"16","author":[{"given":"J.","family":"Sasadeusz","sequence":"first","affiliation":[{"name":"Victorian Infectious Disease Service Royal Melbourne Hospital Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Prince","sequence":"additional","affiliation":[{"name":"Haematology Department Peter MacCallum Centre Melbourne Australia"},{"name":"Department of Medicine University of Melbourne Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schwarer","sequence":"additional","affiliation":[{"name":"Malignant Haematology and Stem Cell Transplant Service The Alfred Hospital Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Szer","sequence":"additional","affiliation":[{"name":"Victorian Infectious Disease Service Royal Melbourne Hospital Melbourne Australia"},{"name":"Department of Medicine University of Melbourne Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stork","sequence":"additional","affiliation":[{"name":"Medical Department Ipsen Pty Ltd Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.L.","family":"Bock","sequence":"additional","affiliation":[{"name":"Development Novartis Vaccines Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Povey","sequence":"additional","affiliation":[{"name":"Department of Statistics GlaxoSmithKline Vaccines Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Vaccine Discovery and Development GlaxoSmithKline Vaccines King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.L.","family":"Innis","sequence":"additional","affiliation":[{"name":"Vaccine Discovery and Development GlaxoSmithKline Vaccines King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01718.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70051-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704870"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.06.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.663486"},{"issue":"3","key":"e_1_2_8_7_1","first-page":"277","article-title":"Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications","volume":"13","author":"Han CS","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-003-0511-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042271"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000122606.88429.8f"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.78.4.757"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.31"},{"key":"e_1_2_8_13_1","unstructured":"Electronic Business Services of Therapeutic Goods Administration.Varilrix\u00aeProduct Information 2013. Available at:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-05277-3(last accessed 3 February 2014)"},{"issue":"2","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/jvi.66.2.1016-1020.1992","article-title":"Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild\u2010type varicella\u2010zoster virus isolates","volume":"66","author":"LaRussa P","year":"1992","journal-title":"J Virol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.5.629"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700909"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.5.840"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0147"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12295","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T22:26:58Z","timestamp":1695508018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/tid.12295"],"URL":"https:\/\/doi.org\/10.1111\/tid.12295","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}